Sanofi (SNYN) - Total Assets
Based on the latest financial reports, Sanofi (SNYN) holds total assets worth MX$128.02 Billion MXN (≈ $7.37 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Sanofi debt service capacity to assess how comfortably operating cash covers total debt obligations.
Sanofi - Total Assets Trend (2013–2025)
This chart illustrates how Sanofi's total assets have evolved over time, based on quarterly financial data. See Sanofi (SNYN) net assets for net asset value and shareholders' equity analysis.
Sanofi - Asset Composition Analysis
Current Asset Composition (December 2025)
Sanofi's total assets of MX$128.02 Billion consist of 24.4% current assets and 75.6% non-current assets.
| Asset Category | Amount (MXN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | MX$0.00 | 6.0% |
| Accounts Receivable | MX$8.41 Billion | 6.6% |
| Inventory | MX$10.21 Billion | 8.1% |
| Property, Plant & Equipment | MX$0.00 | 0.0% |
| Intangible Assets | MX$26.26 Billion | 20.7% |
| Goodwill | MX$41.30 Billion | 32.6% |
Asset Composition Trend (2013–2025)
This chart illustrates how Sanofi's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SNYN market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sanofi's current assets represent 24.4% of total assets in 2025, a decrease from 24.9% in 2013.
- Cash Position: Cash and equivalents constituted 6.0% of total assets in 2025, down from 8.6% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 52.0% of total assets, an increase from 51.0% in 2013.
- Asset Diversification: The largest asset category is goodwill at 32.6% of total assets.
Sanofi Competitors by Total Assets
Key competitors of Sanofi based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
Virbac SA
PA:VIRP
|
France | €1.82 Billion |
|
Aurora Optoelectronics Co Ltd
SHG:600666
|
China | CN¥2.22 Billion |
|
NanJing Pharmaceutical Co Ltd
SHG:600713
|
China | CN¥34.05 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.66 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$112.48 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$207.62 Billion |
Sanofi - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.01 | 1.37 | 1.58 |
| Quick Ratio | 0.22 | 0.69 | 1.21 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | MX$156.00 Million | MX$11.80 Billion | MX$10.93 Billion |
Sanofi - Advanced Valuation Insights
This section examines the relationship between Sanofi's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.22 |
| Latest Market Cap to Assets Ratio | 0.81 |
| Asset Growth Rate (YoY) | -4.5% |
| Total Assets | MX$126.81 Billion |
| Market Capitalization | $102.08 Billion USD |
Valuation Analysis
Near Book Valuation: The market values Sanofi's assets close to their book value (0.81x), suggesting investors view the company's assets at approximately fair value.
Slight Asset Contraction: Sanofi's assets decreased by 4.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Sanofi (2013–2025)
The table below shows the annual total assets of Sanofi from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | MX$126.81 Billion ≈ $7.30 Billion |
-4.51% |
| 2024-12-31 | MX$132.80 Billion ≈ $7.64 Billion |
+5.01% |
| 2023-12-31 | MX$126.46 Billion ≈ $7.28 Billion |
+1.51% |
| 2022-12-31 | MX$124.58 Billion ≈ $7.17 Billion |
+3.61% |
| 2021-12-31 | MX$120.24 Billion ≈ $6.92 Billion |
+4.99% |
| 2020-12-31 | MX$114.53 Billion ≈ $6.59 Billion |
+1.59% |
| 2019-12-31 | MX$112.74 Billion ≈ $6.49 Billion |
+1.19% |
| 2018-12-31 | MX$111.41 Billion ≈ $6.41 Billion |
+11.60% |
| 2017-12-31 | MX$99.83 Billion ≈ $5.75 Billion |
-4.63% |
| 2016-12-31 | MX$104.67 Billion ≈ $6.02 Billion |
+2.30% |
| 2015-12-31 | MX$102.32 Billion ≈ $5.89 Billion |
+5.06% |
| 2014-12-31 | MX$97.39 Billion ≈ $5.60 Billion |
+1.39% |
| 2013-12-31 | MX$96.06 Billion ≈ $5.53 Billion |
-- |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, ty… Read more